

Sarah E S Leary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7288568/publications.pdf>

Version: 2024-02-01

57
papers

3,354
citations

304743

22
h-index

243625

44
g-index

58
all docs

58
docs citations

58
times ranked

4960
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	21.4	381
3	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
4	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	1.6	250
5	Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.	28.9	177
6	Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2015, 33, 2986-2998.	1.6	175
7	Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. <i>Neuro-Oncology</i> , 2019, 21, 83-94.	1.2	108
8	Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience. <i>Cancer</i> , 2013, 119, 2645-2653.	4.1	101
9	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
10	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018, 20, 1547-1555.	1.2	82
11	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
12	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62
13	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	1.6	58
14	The molecular classification of medulloblastoma. <i>Current Opinion in Pediatrics</i> , 2012, 24, 33-39.	2.0	55
15	Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. <i>Cancer Medicine</i> , 2016, 5, 1416-1424.	2.8	53
16	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980.	1.2	52
17	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	1.2	51
18	Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma. <i>Cancer</i> , 2011, 117, 3262-3267.	4.1	45

#	ARTICLE	IF	CITATIONS
19	Survival After Relapse of Medulloblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 269-273.	0.6	43
20	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
21	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. <i>Molecular Cancer Research</i> , 2018, 16, 1491-1498.	3.4	39
22	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
23	Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study. <i>Neuro-Oncology</i> , 2022, 24, 974-983.	1.2	30
24	NKG2D ligand expression in pediatric brain tumors. <i>Cancer Biology and Therapy</i> , 2016, 17, 1253-1265.	3.4	26
25	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
26	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28879.	1.5	24
27	Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. <i>Journal of Neuro-Oncology</i> , 2020, 148, 607-617.	2.9	21
28	A phase I/II study of LDE225, a smoothed (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9519-9519.	1.6	21
29	Surveillance magnetic resonance imaging for isolated optic pathway gliomas: is gadolinium necessary?. <i>Pediatric Radiology</i> , 2018, 48, 1472-1484.	2.0	19
30	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAFV600 mutant relapsed refractory low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10506-10506.	1.6	17
31	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). <i>Neuro-Oncology</i> , 2022, 24, 1178-1190.	1.2	13
32	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 67.	5.2	12
33	Description of a new oncogenic mechanism for atypical teratoid rhabdoid tumors in patients with ring chromosome 22. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 245-249.	1.2	11
34	Characteristics of patients ≥ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
35	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2017, 23, 6062-6069.	7.0	7
36	A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27217.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Gliomas in the context of Li-Fraumeni syndrome: An international cohort.. Journal of Clinical Oncology, 2019, 37, 1517-1517.	1.6	6
38	Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy. Pediatric Dermatology, 2021, 38, 18-30.	0.9	6
39	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6
40	A phase II/III randomized, blinded study of tozuleristide for fluorescence imaging detection during neurosurgical resection of pediatric primary central nervous system (CNS) tumors: PNOC012 (Pacific) Tj ETQq0 0 0rgBT /Overlock 10 Tf		
41	Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor. Scientific Reports, 2022, 12, 5386.	3.3	3
42	Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report. Neuro-Oncology Advances, 0, , .	0.7	3
43	Preliminary exploratory data analysis of simulated national clinical data research network for future use in annotation of a rare tumor biobanking initiative. , 2017, , .		2
44	Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of Children. JCO Precision Oncology, 2018, 2, 1-13.	3.0	2
45	Unusual Radiographic Presentation of Intracranial Mature Teratoma and Resection via Supraorbital Approach. World Neurosurgery, 2019, 122, 81-84.	1.3	2
46	Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma. journal of applied laboratory medicine, The, 2021, 6, 550-553.	1.3	2
47	Two cases of pineal anlage tumor with molecular analysis. Pediatric Blood and Cancer, 2022, 69, e29596.	1.5	2
48	Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma and individual participant data meta-analysis (IPDMA). Journal of Neuro-Oncology, 2021, 155, 155-163.	2.9	1
49	Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry. Neuro-Oncology, 2022, , .	1.2	1
50	GCT-18. Endoscopic third ventriculostomy (ETV) and tumor biopsy are not associated with relapse rate or patterns in primary central nervous system (CNS) germ cell tumor (GCT). Neuro-Oncology, 2022, 24, i58-i58.	1.2	1
51	NSRG-15. FIRST IN HUMAN USE OF CANVAS IMAGING SYSTEM FOR VISUALIZATION OF TOZULERISTIDE-INDUCED TUMOR FLUORESCENCE. Neuro-Oncology, 2018, 20, i148-i148.	1.2	0
52	A phase I trial of MK 2206 in children with refractory solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 9581-9581.	1.6	0
53	IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 2018, 20, i100-i101.	1.2	0
54	NIMG-11. VOLUMETRIC ENDPOINTS IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): COMPARISON TO CROSS-SECTIONAL MEASURES AND CORRELATION WITH OUTCOMES. Neuro-Oncology, 2021, 23, vi129-vi130.	1.2	0

#	ARTICLE	IF	CITATIONS
55	SURG-12. Endoscopic evaluation of ventricular dissemination in primary central nervous system (CNS) germ cell tumors (GCTs). <i>Neuro-Oncology</i> , 2022, 24, i144-i144.	1.2	0
56	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). <i>Neuro-Oncology</i> , 2022, 24, i36-i36.	1.2	0
57	EPCT-06. Phase I study of ribociclib and everolimus post-radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): Updated report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). <i>Neuro-Oncology</i> , 2022, 24, i36-i37.	1.2	0